Sec Form 3 Filing - Markovich Rebecca @ Talis Biomedical Corp - 2023-04-21

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Markovich Rebecca 2. Issuer Name and Ticker or Trading Symbol Talis Biomedical Corp [ TLIS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Interim CFO (Last) (First) (Middle) C/O TALIS BIOMEDICAL CORPORATION, 1100 ISLAND DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 04/21/2023 (Street) REDWOOD CITY, CA94065 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock option (right to buy) $ 2.14 ( 1 ) 02/10/2032 Common Stock 79,000 D Stock option (right to buy) $ 1.03 ( 2 ) 06/01/2032 Common Stock 60,000 D Stock option (right to buy) $ 0.49 ( 1 ) 04/07/2033 Common Stock 70,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Markovich Rebecca C/O TALIS BIOMEDICAL CORPORATION 1100 ISLAND DRIVE REDWOOD CITY, CA94065 Interim CFO Signatures /s/ Gillian Green, Attorney-in-Fact for Rebecca Markovich 04/25/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/48th of the shares underlyingthis option shall vest monthly thereafter over 36 months. ( 2 )1. 1/3 of awards vest as follows: 25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencementdate of June 1, 2022 (VCD) and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months. 2. 1/3 of the sharesshall vest on the seventh anniversary of the VCD, subject to optionholder's continuous service as of such date, provided that such vesting shallbe subject to acceleration based upon certain pre-determined commercial and regulatory milestones. 3. 1/3 of the shares shall vest on theseventh anniversary of the VCD, subject to optionholder's continuous service as of such date, provided that such vesting shall be subject topartial or full acceleration based on pre-determined closing prices of the Company's common stock sustained for a certain number of consecutivetrading days.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.